2.5% Input 
GFP GFP-Rab7 (Diacovich et al., 2009) Myc-SifA(1-336) aa 1-336 S. typhimurium (Boucrot et al., 2005) pCMV-HA-SKIP Full length human SKIP (Diacovich et al., 2009) 
Supplemental Tables
siPlek#1 PLEKHM1 (cDNA) GCAAAGUCCUGGCAUCCUA siPlek#2 PLEKHM1 (cDNA) GAACGCGUCUCUGUACGAG siVps11#1 VPS11 (cDNA) GAAACGAGAUCUCCAUGAU siVps11#2 VPS11 (cDNA) GAACGUCCAGUCCUAUAUA siVps41#1 VPS41 (cDNA) GAGAAUGAAUGUAGAGAUU siVps41#2 VPS41 (cDNA) GACAAACCACCAUUUAUUA siRab7-2 RAB7A (cDNA) GUACAAAGCCACAAUAGGA siRab7-3 RAB7A (cDNA) AAACGGAGGUGGAGCUGUA
Supplemental Experimental Procedures
Materials. See also Supplementary Tables S2 and S3 . cDNAs, antibodies and reagents: Plasmids used in the study are described in Table S2 . Site-directed mutagenesis was performed by PCR to introduce desired mutations in the PLEKHM1 constructs. The DNA sequence was verified by sequencing. The following antibodies were used in the study: mouse monoclonal anti-GFP (Sigma), rabbit monoclonal AntiRab7 (clone D95F2; Cell signaling technologies/NEB), rat monoclonal anti-HA (clone 3F10; Roche), mouse monoclonal anti-HA (Covance), mouse monoclonal anti-myc (Santa Cruz), mouse monoclonal anti-FLAG® M2, mouse monoclonal anti-Vinculin (Sigma Aldrich), anti-LAMP2 (clone H4B4; Developmental Studies Hybridoma Bank), mouse monoclonal anti-LAMP1 (DSHB, H4A3) and rabbit polyclonal anti-Vps11 (Abcam). The anti-PLEKHM1 (IG1132) antibody was generated by immunGlobe ® . Briefly, a chemically synthesized peptide (human PLEKHM1 aa626-647) was used for immunization. All sera were routinely affinity purified using a fully automated FPLC-based system (immunoGlobe, Himmelstadt, Germany). Secondary HRP conjugated antibodies, goat anti-mouse and goat anti-rabbit IgGs were used for immunoblotting. Donkey anti-mouse Cy3 and Cy5-conjugated secondary antibodies, Donkey Anti-goat Cy5, Donkey anti-rabbit Cy3 (Jackson Immuno Research), Donkey anti-Rat-Alexa-488 Anti-Rabbit IgG Alexa405, Anti-mouse IgM Alexa568, Anti-mouse IgG1 Alexa647 (Molecular Probes) and Donkey anti-Rabbit-647 (Invitrogen) were used for immunofluorescence studies. GeneJuice ® (Merck) was used to transfect HEK293T cells and Turbofect (ThermoScientific) for HeLa and U2OS cells. GFPTrap ® was purchased from ChromoTek, anti-FLAG-M2 and anti-HA beads from Sigma. Control and PLEKHM1 validated shRNA (lentiviral particles) were obtained from SIGMA Aldrich. Dharmacon siRNA smartpool against human PLEKHM1, Rab7, Vps39 and Vps41 were obtained from ThermoScientific and individually tested for efficient knockdown. Sequences of oligos used in this study are described in Table  S3 .
Protein expression and purification GST and MBP fusion proteins were cloned into pGEX-4T-1 (GE Healthcare) and pMAL-c2x (NEB), respectively, and expressed in Escherichia coli BL21 (DE3) cells in LB medium. Expression was induced by addition of 0.2 mM IPTG and cells were incubated at 16°C overnight. Harvested cells were lysed using sonication in a lysis buffer (20 mM Tris-HCl pH 7.5, 10 mM EDTA, 5 mM EGTA, 150mM NaCl) and the supernatant was subsequently applied to Glutathione Sepharose 4B beads (GE Healthcare), Ni-NTA agarose (QIAGEN) or amylose resin (NEB). After several washes, fusion protein-bound beads were eluted with 20mM Maltose (MBP) or 250mM imidazole (6xHis) used directly in GST pulldown assays.
Microscope imaging. Cells were plated on glass cover slips, and 24 hours post transfection or after treatment at the indicated timepoints were fixed by 2 % (wt/vol) paraformaldehyde for 20 min. siRNA cells were stained and imaged 48hr post transfection treatment. Cells were permeabilized with a 0.2% Triton X-100 solution in PBS at room temperature for 2 min. All cells were blocked in PBS containing 10% foetal bovine serum (FBS) at 4 °C overnight. Primary and secondary antibodies were diluted in the blocking solution, and washes were performed in 0.1% Tween 20 in PBS. DAPI (Molecular Probes) was added during primary antibody incubation. The coverslips were mounted on 10 µl of aqueous mounting medium (Mowiol) and placed on a glass holder. Images were acquired by the Leica SP8 laser-scanning microscope (Leica). Images shown are representative of experiments carried out at least twice. Live cell imaging was carried out in non-phenol red containing DMEM buffered with HEPES (Invitrogen). Images were taken every 2 seconds for a total of 5 minutes on a CSU-X1 Real-Time Confocal System with Nipkow spinning disk (Visitron) at a disk speed of 3000rpm. Image analysis was performed using either ImageJ or Volocity (Perkin-Elmer) software.
Mass spectrometry. For SILAC labeling, HeLa cells were cultured in media supplemented with either L-arginine-12 C 6 14 N 4 (Arg0) and L-lysine-12 C 6 14 N 2 (Lys0) or Larginine-13 C 6 15 N 4 (Arg10) and L-lysine-U-13 C 6 15 N 2 (Lys8) as described previously (Ong et al., 2002) . SILAC labeled cells were lysed using GTPase lysis buffer and incubated with either GDP-loaded GST-Rab7 or GTPγS GST-Rab7 for 1 hr at 4°C. GST-Rab7 was precipitated and washed as in the GFP co-precipitation protocol. Eluates were mixed 1:1 (v/v) and run on SDS-PAGE. The gel lane was cut into 10 slices followed by tryptic In-Gel digestion and the resulting peptides were analyzed on an EasyLC nano-HPLC (Proxeon Biosystems) coupled to an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). All data analysis was performed using MaxQuant software (v1.0.14.3) (Cox and Mann, 2008) .
Cell lines/Generation of stable cells. HeLa Kyoto (Neumann et al., 2006) , HEK293T, and U2OS cells were obtained from ATCC and grown in DMEM supplemented with 10% fetal bovine serum, 1% sodium pyruvate, 1% non-essential amino acids and penicillin/streptomycin. Stable knockdown of PLEKHM1 or control cells were generated using lentiviral infection of cells and selection with 5µg/ml puromycin. Cells were routinely maintained in 1µg/ml puromycin. U2OS PLEKHM1-GFP cells were transfected using Turbofect (Roche) and PLEKHM1 cloned into pEGFP-N1 (Clontech), left for 48h and placed into G418/neomycin media which was replaced every 48h until section was complete. The HeLa FRT/TO cell line for creating stable cell lines using the Flp-In™ T-REx™ System (Invitrogen) was kindly provided by S. Taylor (University Manchester) and maintained as described (Tighe et al., 2008) . PLEKHM1-GFP and PLEKHM1-2xFlag was cloned into pcDNA5/FRT/TO vector and transfected with recombinase pOG44 into Flp-In™ T-REx™ tetracycline transactivator HeLa cells. Hygromycin-resistant colonies were pooled and expanded, and transgene expression was induced with 100 ng/ml tetracycline (Sigma-Aldrich). Cells were continuously maintained in their respective selection-containing media.
Macrophage isolation. Peritoneal macrophages were harvested by peritoneal lavage 5 days after injection of thioglycolate and cultured in RPMI 1640 (Invitrogen) under serum-free conditions as described (Schaefer et al., 2005) .
Immunoprecipitation. For endogenous protein immunoprecipitation, supernatants (10 min, 1000 x g) from cells lysed in GTPase lysis buffer (50 mM Tris.HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100) supplemented with Complete protease inhibitor cocktail (Roche) were incubated with a primary antibody overnight at 4°C (under rotation) and protein A or G Sepharose (60min), centrifuged and washed a minimum of 3 times with lysis buffer. Precipitated proteins were detected by immunoblot analysis using chemiluminescence based detection. For coprecipitation of epitope-tagged proteins, 3µl GFP-Trap® beads (Chromotek) or 5µl anti-Flag® M2 agarose, or 15µl anti-HA beads (Sigma) were incubated with lysates for a total of 60 mins at 4°C rotation and pellets washed 3 times with lysis buffer and 4 times with wash buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 2mM MgCl 2 , 0.1% Triton X-100) prior to loading onto SDS-PAGE gels for analysis.
